Chinese cancer diagnostics firm SeekIn said Monday that it has received the CE mark for its PanCanSeek Cancer Mutation Detection Kit and now intends to market the test in the European Union and other regions that recognize the designation.

Cofactor Genomics on Wednesday announced the commencement of a study of its OncoPrism assay in non-small cell lung cancer (NSCLC).

A team from Stanford University, Columbia University, the New York Genome Center, and elsewhere has uncovered somatic tandem repeat expansions in tumors from a wide range of cancer types, including a potentially targetable repeat expansion in a subset of kidney cancers.

Bioinformatics company Envisagenics said Tuesday that it has formed a research collaboration with Queen Mary University of London and the technology-transfer arm of Cancer Research UK to explore the role of "alternative" splicing in hematopoietic cancer.

Agilent Technologies and Qiagen said on Monday and Tuesday respectively that they have gained US Food and Drug Administration approval of companion diagnostic assays for use with a new treatment for patients with advanced non-small cell lung cancer.

Scientists from the National University of Singapore (NUS) have discovered a novel low-cost method of testing for cancers. Called the Heatrich-BS assay, this new test sequences clinical samples that have been heated in order to isolate cancer-specific signatures found in a patient’s blood.

Liquid biopsy firm SeekIn said Monday that it has received a CE mark for its cancer recurrence monitoring test, SeekInCure, and is preparing to launch assay kits in the European Union and other countries that recognize the designation.

Duke Cancer Institute researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire, driving hyper-progression of melanoma cells instead of unleashing the immune system to fight them.

Biodesix said Monday that it has been awarded a US Federal Supply Schedule contract for cancer testing of covered patients served by the Veterans Health Administration and Military Health System.

Illumina said on Tuesday that it has entered into a strategic research collaboration with AstraZeneca on drug target discovery.